

Table 2. Demographic and treatment safety data for the phase 1 trial of high-dose oral *N*-acetylcysteine in cystic fibrosis

	Subject information								Adverse effects			
	Trial ID	Age (yrs)	Gender	Genotype group	Pancr. Insuff.	P aer. infection	FEV1 % pred	Compliance (%)	Clinical monitoring	Patient reporting	Duration (days)	Probable cause(s)
COHORT #1 1.8 g/d	001	11	F	CH HO	PI	N	110	88	None	Headache	1	Dehydration
	002	11	F		PI	Y	50	93	None	Increased cough, sputum; decreased peak flow and exercise tolerance	9	Infection
	003	40	F	CH	PI	N	67	96	None	Heartburn	8	Drug
	004	18	F	CH	PI	Y	82	93	None	Heartburn	5	Drug
	005	16	F	HO	PI	N	108	76	None	Nausea	3	Drug
	006	32	F	HO	PI	Y	47	96	None	Heartburn	19	Drug
	6/6 completed	21 (11-40)	6 F	3 CH 3 HO	6 PI	3 Y 3 N	77 (47-110)	90	0/6	Drug caused: heartburn, nausea	9	4/6 (all mild)
COHORT #2 2.4 g/d	007	14	F	CH	PI	Y	59	87	None	None	N/A	N/A
	008	14	F	HO	PI	Y	53	94	None	Sore throat	1	Infection
	009	12	M	CH	PI	Y	88	96	None	Headache, mild cough	28	Ibuprofen withdrawal
	010	28	F	HO	PI	Y	69	100	None	Bad taste	28	Drug
	011	19	F	OT	PI	Y	44	93	None	Rash	3	Contact dermatitis
	012	44	F	HO	PS	Y	65	92	None	Increased cough, heartburn	6,1	N/A
	6/6 completed	22 (12-44)	5 F 1 M	2 CH 3 HO 1 OT	5 PI 1 PS	6 Y	63 (44-88)	94	0/6	Drug caused: bad taste	28	1/6 (mild)
COHORT #3 3.0 g/d	013	27	M	CH	PI	Y	89	94	None	Heartburn	10	Drug
	014	35	F	CH	PS	Y	93	94	None	Cold symptoms	1	Infection
	015	38	M	CH	PI	Y	58	95	None	Constipation	2	Intestinal obstruction
	016	23	M	HO	PI	N	89	93	None	Increased cough, chest pain	10	Lung disease
	017	31	M	CH	PI	Y	49	100	None	Weight loss, increased cough, flatulence	28	Lung disease; Drug
	018	31	M	CH	PS	Y	55	94	None	Increased sputum	18	N/A
	6/6 completed	31 (23-38)	1 F 5 M	5 CH 1 HO	4 PI 2 PS	5 Y 1 N	72 (49-93)	95	0/6	Drug caused: heartburn, flatulence	19	2/6 (all mild)
TOTAL	18/18 completed	25 (11-44)	12 F 6 M	10 CH 7 HO 1 OT	15 PI 3 PS	14 Y 4 N	71 (44-110)	93	0 / 18	Drug caused: bad taste, heartburn, nausea, flatulence	14	7/18 (all mild)

CH, 1 ΔF508 and 1 other mutation; HO, ΔF508 / ΔF508; OT, other; P aer., *P. aeruginosa*, Pancr. Insuff, pancreatic insufficient.